Table 4.
Fel-O-Vax-induced Ab immunity in passive-transfer (PT) protection against homologous FIVPet and heterologous subtype-B FIVFC1 a.
| PT Study | PT of Serum or Abs | Anti-Pet NAb Titer (Range) b | Anti-FC1 Nab Titer (Range) b | Challenge (25 CID50) | Protection Rate (p-Value) c,d | Combined Protection Rate (p-Value) c,d |
|---|---|---|---|---|---|---|
| 1A1 | Fel-O-Vax-induced pooled serum Abs | 513 (50–1000) | <5 | FIV-Pet | 4/4 (0.0286) | 11/12 (<0.0001) |
| 1A2 | Fel-O-Vax-induced purified Abs | 639 (10–1000) | 50 in only 1 cat e | FIV-Pet | 7/8 (0.0014) | - |
| 1B1 | Pooled control cat serum or saline | <5 | <5 | FIV-Pet | 0/4 | 0/11 |
| 1B2 | Purified non-vaccine Abs or saline | <5 | <5 | FIV-Pet | 0/7 | - |
| 2A | Fel-O-Vax-induced purified Abs | 630 (50–1000) | 30 in only 2 cats e | FIV-FC1 | 0/5 (NS) | 0/5 (NS) |
| 2B | Purified non-vaccine Abs or saline | <5 | <5 | FIV-FC1 | 0/5 | 0/5 |
aTable 4 adapted from reference [48]. b Average neutralizing antibody (NAb) titer and range to either FIVPet (Pet) or FIVFC1 (FC1) present in PT cats at 6 days post-PT or 1 week post-challenge. c Comparing Groups A versus B in a two-tailed Fisher Exact Test for p-value (italics) with p < 0.05 as significant (bolded italics); not significant (NS). d Statistics based on 1A1 vs. 1B1 (p = 0.0286), 1A2 vs. 1B2 (p = 0.0014), or A vs. B (p < 0.0001) or (NS). e Only one cat in Group 1A2 and two cats in Group 2A had anti-FIVFC1 NAb titer of 50 and 30, respectively.